Kenvue (NYSE:KVUE - Free Report) had its target price increased by Citigroup from $21.00 to $22.00 in a research note published on Monday, MarketBeat Ratings reports. Citigroup currently has a neutral rating on the stock.
A number of other research firms have also recently weighed in on KVUE. UBS Group cut their price target on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Barclays decreased their target price on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research report on Monday, April 14th. Canaccord Genuity Group boosted their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Redburn Atlantic assumed coverage on shares of Kenvue in a report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective for the company. Finally, Piper Sandler upped their target price on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Eight research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $24.42.
Read Our Latest Report on Kenvue
Kenvue Stock Performance
KVUE stock traded up $0.69 during trading on Monday, hitting $23.42. 22,595,142 shares of the company's stock traded hands, compared to its average volume of 17,088,173. The stock has a fifty day moving average price of $22.91 and a two-hundred day moving average price of $22.41. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue has a 52 week low of $17.67 and a 52 week high of $24.46. The stock has a market capitalization of $44.93 billion, a price-to-earnings ratio of 44.19, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts anticipate that Kenvue will post 1.14 EPS for the current fiscal year.
Kenvue Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.50%. The ex-dividend date is Wednesday, May 14th. Kenvue's dividend payout ratio is presently 154.72%.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Clarius Group LLC purchased a new position in Kenvue during the 1st quarter worth approximately $217,000. GSB Wealth Management LLC raised its position in Kenvue by 2.3% during the first quarter. GSB Wealth Management LLC now owns 152,765 shares of the company's stock valued at $3,663,000 after buying an additional 3,443 shares during the period. San Luis Wealth Advisors LLC purchased a new stake in Kenvue in the 1st quarter worth about $567,000. QRG Capital Management Inc. grew its stake in Kenvue by 54.8% during the 1st quarter. QRG Capital Management Inc. now owns 15,832 shares of the company's stock valued at $380,000 after acquiring an additional 5,607 shares in the last quarter. Finally, Sagespring Wealth Partners LLC increased its holdings in shares of Kenvue by 45.2% in the 1st quarter. Sagespring Wealth Partners LLC now owns 20,640 shares of the company's stock valued at $495,000 after purchasing an additional 6,430 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.
About Kenvue
(
Get Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Articles
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
